At the same time, we verified the expression levels and status of well-known molecular markers including MGMT promoter methylation, IDH1 mutant, and co-deletion of 1p19q in low-grade glioma patients (WHOII, WHOIII) between high and low expression of SYP (Supplementary Figures S1A–C). The gene discussed is IDH1; the disease is central nervous system cancer.